Fish Skin (Kerecis Omega 3 Wound®) vs Suprathel® in Deep Dermal Burns: An Intraindividual Comparison of Long-Term Scar Quality
Journal of Burn Care & Research · 2026
DOI: 10.1093/jbcr/irag034 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Burn Care & Research, 2026. Verfasst von Wolfram Heitzmann und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Plastic, Reconstructive, Hand and Burn Surgery, Hospital Cologne Merheim, University of Witten/Herdecke, Cologne, North Rhine-Westphalia 51…. Hauptthemen laut MEDLINE: Burns, Debridement, Cicatrix, Bandages. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Gefördert von: Kerecis®.
Abstract (Originalsprache)
Deep dermal burns pose a high risk for long-term functional and esthetic impairments. The choice of wound dressing following enzymatic debridement plays a critical role in modulating the healing response and scar formation. While both Kerecis® and Suprathel® have demonstrated clinical safety and efficacy, comparative long-term data remain limited. Kerecis®, being associated with accelerated wound healing in previous studies, was compared to Suprathel® in this study to evaluate functional and esthetic scar outcomes using an intraindividual study design. This prospective, intraindividual study included 21 patients with deep dermal burns of the hands and feet, who underwent enzymatic debridement using Nexobrid®. Each patient received treatment with both Kerecis® and Suprathel® on comparable burn areas, ensuring consistency in the comparison. Scar outcomes were evaluated at 3-, 6-, and 12-month post-treatment. Objective parameters such as skin pigmentation, elasticity, transepidermal water loss, and oxygen saturation were measured. Additionally, subjective esthetic, clinical, and functional parameters were assessed using the Patient and Observer Scar Assessment Scale (POSAS) and the Vancouver Scar Scale (VSS). At the 12-month follow-up, objective measurements demonstrated significant differences in erythema and gross elasticity, with Kerecis® exhibiting comparatively favorable outcomes. Subjective analyses indicated a significantly improved scar height and pliability for the Kerecis® group in the VSS and the POSAS observer scale. However, no significant differences were found in the POSAS Patient Scale. Both dressings provide satisfactory long-term scar outcomes in enzymatically debrided deep dermal burns, with Kerecis® showing trends toward more physiological scar characteristics in selected parameters, warranting further patient-centered research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Clinic of Plastic, Reconstructive, Hand and Burn Surgery, Hospital Cologne Merheim, University of Witten/Herdecke, Cologne, North Rhine-Westphalia 51109, Germany.
- Institute for Research in Operative Medicine (IFOM), Faculty of Health, Witten/Herdecke University, Cologne, North Rhine-Westphalia 51109, Germany.
ORCID-Profile: Wolfram Heitzmann, Rolf Lefering
Förderung
- Kerecis®
Zitieren
APA
Heitzmann, W., Enzmann, J., von Kohout, M., Mattern, M. M., Akkan, J., Fuchs, P. C., Lefering, R., & Schiefer, J. L. (2026). Fish Skin (Kerecis Omega 3 Wound®) vs Suprathel® in Deep Dermal Burns: An Intraindividual Comparison of Long-Term Scar Quality. Journal of Burn Care & Research. https://doi.org/10.1093/jbcr/irag034
Vancouver
Heitzmann W, Enzmann J, von Kohout M, Mattern MM, Akkan J, Fuchs PC, et al. Fish Skin (Kerecis Omega 3 Wound®) vs Suprathel® in Deep Dermal Burns: An Intraindividual Comparison of Long-Term Scar Quality. Journal of Burn Care & Research. 2026. doi:10.1093/jbcr/irag034
BibTeX
@article{Heitzmann2026,
author = {Heitzmann, Wolfram and Enzmann, Julia and von Kohout, Maria and Mattern, Maximilian Maria and Akkan, Jan and Fuchs, Paul Christian and Lefering, Rolf and Schiefer, Jennifer Lynn},
title = {Fish Skin (Kerecis Omega 3 Wound®) vs Suprathel® in Deep Dermal Burns: An Intraindividual Comparison of Long-Term Scar Quality},
journal = {Journal of Burn Care & Research},
year = {2026},
doi = {10.1093/jbcr/irag034}
}
EUVIMED